Clinical characteristics and response to therapy of 7 patients with primary non-Hodgkin's lymphoma of the stomach and 1 patient with double malignancy are analysed. All patients but one were gastrectomized and subjected to the chemotherapy (COP, CHOP or leukeran + prednison) programme. In 3 patients (2 with lymphocytic lymphoma and 1 with lymphoplasmocytic lymphoma) no recurrence occurred in the course of the observation time ranging from 18 to 20 months. In one patient with centrocytic lymphoma extra-abdominal recurrence was successfully treated with leukeran + prednison. 4 patients (2 with immunoblastic lymphoma and 1 with lymphoplasmocytic lymphoma) with abdominal or extra-abdominal recurrence died after a period ranging from 4 to 29 months despite more aggressive therapy with CHOP programme. Opinions concerning pathogenesis and treatment strategy of those lymphomas are presented too.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study.
Lancet Oncol
January 2025
Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Faculty of Health, Medicine, and Social Care, Anglia Ruskin University, Cambridge, UK; Department of Haematology, University of Cambridge, Cambridge, UK. Electronic address:
Background: Procarbazine-containing chemotherapy regimens are associated with cytopenias and infertility, suggesting stem-cell toxicity. When treating Hodgkin lymphoma, procarbazine in escalated-dose bleomycin-etoposide-doxorubicin-cyclophosphamide-vincristine-procarbazine-prednisolone (eBEACOPP) is increasingly replaced with dacarbazine (eBEACOPDac) to reduce toxicity. We aimed to investigate the impact of this drug substitution on the mutation burden in stem cells, patient survival, and toxicity.
View Article and Find Full Text PDFNon-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
Cochrane Database Syst Rev
November 2024
Cochrane Kidney and Transplant, Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Australia.
Background: About 80% of children with steroid-sensitive nephrotic syndrome (SSNS) have relapses. Of these children, half will relapse frequently, and are at risk of adverse effects from corticosteroids. While non-corticosteroid immunosuppressive medications prolong periods of remission, they have significant potential adverse effects.
View Article and Find Full Text PDFGroup I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis.
Sci Rep
January 2024
Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.
We aimed to summarize the cancer risk among patients with indication of group I pharmaceuticals as stated in monographs presented by the International Agency for Research on Cancer working groups. Following the PRISMA guidelines, a comprehensive literature search was conducted using the PubMed database. Pharmaceuticals with few studies on cancer risk were identified in systematic reviews; those with two or more studies were subjected to meta-analysis.
View Article and Find Full Text PDFInterventions for focal segmental glomerulosclerosis in adults.
Cochrane Database Syst Rev
February 2022
Sydney School of Public Health, The University of Sydney, Sydney, Australia.
Article Synopsis
- - Focal segmental glomerulosclerosis (FSGS) is a kidney disease that can be classified into primary, genetic, or secondary types, with only about 20% of patients achieving remission with treatment, and half eventually facing kidney failure.
- - This review aims to evaluate the effectiveness and safety of both immunosuppressive and non-immunosuppressive treatments in adults suffering from FSGS.
- - The analysis included 15 studies with 560 participants, focusing on randomized controlled trials to compare various treatment regimens, but results were inconclusive regarding corticosteroids versus placebo.
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
Br J Haematol
July 2021
Department of Haematology, Oxford University Hospital NHS Foundation Trust, Oxford, UK.
Mantle cell lymphoma (MCL) presenting in elderly, unfit patients represents a clinical challenge. Front-line 'attenuated' or low-intensity immunochemotherapy is often employed, although outcomes are relatively unexplored. We report outcomes of attenuated immunochemotherapy in 95 patients with MCL across 19 centres in the UK and Ireland considered unfit for full-dose rituximab-bendamustine or rituximab-cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!